Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2004

Open Access 01-12-2004 | Research

PTTG/securin activates expression of p53 and modulates its function

Authors: Tariq Hamid, Sham S Kakar

Published in: Molecular Cancer | Issue 1/2004

Login to get access

Abstract

Background

Pituitary tumor transforming gene (PTTG) is a novel oncogene that is expressed abundantly in most tumors. Overexpression of PTTG induces cellular transformation and promotes tumor formation in nude mice. PTTG has been implicated in various cellular processes including sister chromatid separation during cell division as well as induction of apoptosis through p53-dependent and p53-independent mechanisms. The relationship between PTTG and p53 remains unclear, however.

Results

Here we report the effects of overexpression of PTTG on the expression and function of p53. Our results indicate that overexpression of PTTG regulates the expression of the p53 gene at both the transcriptional and translational levels and that this ability of PTTG to activate the expression of p53 gene is dependent upon the p53 status of the cell. Deletion analysis of the p53 gene promoter revealed that only a small region of the p53 gene promoter is required for its activation by PTTG and further indicated that the activation of p53 gene by PTTG is an indirect effect that is mediated through the regulation of the expression of c-myc, which then interacts with the p53 gene promoter. Our results also indicate that overexpression of PTTG stimulates expression of the Bax gene, one of the known downstream targets of p53, and induces apoptosis in a human embryonic kidney cell line (HEK293). This stimulation of bax expression by PTTG is indirect and is mediated through modulation of p53 gene expression.

Conclusions

Overexpression of PTTG activates the expression of p53 and modulates its function, with this action of PTTG being mediated through the regulation of c-myc expression. PTTG also up-regulates the activity of the bax promoter and increases the expression of bax through modulation of p53 expression.
Appendix
Available only for authorised users
Literature
1.
Pei L, Melmed S: Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Mol Endocrinol. 1997, 11: 433-441.CrossRefPubMed
2.
Kakar SS, Jennes L: Molecular cloning and characterization of the tumor transforming gene (TUTR1): a novel gene in human tumorigenesis. Cytogenet Cell Genet. 1999, 84: 211-216.CrossRefPubMed
3.
Zhang X, Horwitz GA, Prezant TR, Valentini A, Nakashima M, Bronstein MD, Melmed S: Structure, expression, and function of human pituitary tumor-transforming gene (PTTG). Mol Endocrinol. 1999, 13: 156-166.CrossRefPubMed
4.
5.
Heaney AP, Nelson V, Fernando M, Horwitz G: Transforming events in thyroid tumorigenesis and their association with follicular lesions. J Clin Endocrinol Metab. 2001, 86: 5025-5032.CrossRefPubMed
6.
Heaney AP, Singson R, McCabe CJ, Nelson V, Nakashima M, Melmed S: Expression of pituitary-tumour transforming gene in colorectal tumours. Lancet. 2000, 355: 716-719.CrossRefPubMed
7.
Puri R, Tousson A, Chen L, Kakar SS: Molecular cloning of pituitary tumor transforming gene 1 from ovarian tumors and its expression in tumors. Cancer Lett. 2001, 163: 131-139.CrossRefPubMed
8.
Solbach C, Roller M, Fellbaum C, Nicoletti M, Kaufmann M: PTTG mRNA expression in primary breast cancer: a prognostic marker for lymph node invasion and tumor recurrence. Breast. 2004, 13: 80-81.CrossRefPubMed
9.
Saez C, Pereda T, Borrero JJ, Espina A, Romero F, Tortolero M, Pintor-Toro JA, Segura DI, Japon MA: Expression of hPTTG proto-oncogene in lymphoid neoplasias. Oncogene. 2002, 21: 8173-8177.CrossRefPubMed
10.
Boelaert K, McCabe CJ, Tannahill LA, Gittoes NJ, Holder RL, Watkinson JC, Bradwell AR, Sheppard MC, Franklyn JA: Pituitary tumor transforming gene and fibroblast growth factor-2 expression: potential prognostic indicators in differentiated thyroid cancer. J Clin Endocrinol Metab. 2003, 88: 2341-2347.CrossRefPubMed
11.
Saez C, Japon MA, Ramos-Morales F, Romero F, Segura DI, Tortolero M, Pintor-Toro JA: hPTTG is over-expressed in pituitary adenomas and other primary epithelial neoplasias. Oncogene. 1999, 18: 5473-5476.CrossRefPubMed
12.
Shibata Y, Haruki N, Kuwabara Y, Nishiwaki T, Kato J, Shinoda N, Sato A, Kimura M, Koyama H, Toyama T, Ishiguro H, Kudo J, Terashita Y, Konishi S, Fujii Y: Expression of PTTG (pituitary tumor transforming gene) in esophageal cancer. Jpn J Clin Oncol. 2002, 32: 233-237.CrossRefPubMed
13.
Ramaswamy S, Ross KN, Lander ES, Goulb TR: A molecular signature of metastasis in primary solid tumors. Nat Genet. 2003, 33: 49-54.CrossRefPubMed
14.
Ramos-Morales F, Dominguez A, Romero F, Luna R, Multon MC, Pintor-Toro JA, Tortolero M: Cell cycle regulated expression and phosphorylation of hPTTG proto-oncogene product. Oncogene. 2000, 19: 403-409.CrossRefPubMed
15.
Yu R, Ren S-G, Horwitz GA, Wang Z, Melmed S: Pituitary Tumor Transforming Gene (PTTG) Regulates Placental JEG-3 Cell Division and Survival: Evidence from Live Cell Imaging. Mol Endocrinol. 2000, 14: 1137-146.CrossRefPubMed
16.
Zou H, McGarry TJ, Bernal T, Kirschner MW: Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. Science. 1999, 285: 418-422.CrossRefPubMed
17.
Romero F, Multon MC, Ramos-Morales F, Dominguez A, Bernal JA, Pintor-Toro JA, Tortolero M: Human securin, hPTTG, is associated with Ku heterodimer, the regulatory subunit of the DNA-dependent protein kinase. Nucleic Acids Res. 2001, 29: 1300-1307.PubMedCentralCrossRefPubMed
18.
Ishikawa H, Heaney AP, Yu R, Horwitz GA, Melmed S: Human Pituitary Tumor-Transforming Gene Induces Angiogenesis. J Clin Endocrinol Metab. 2001, 86: 867-874.PubMed
19.
Hunter JA, Skelly RH, Aylwin SJ, Geddes JF, Evanson J, Besser GM, Monson JP, Burrin JM: The relationship between pituitary tumour transforming gene (PTTG) expression and in vitro hormone and vascular endothelial growth factor (VEGF) secretion from human pituitary adenomas. Eur J Endocrinol. 2003, 148: 203-211.CrossRefPubMed
20.
Pei L: Activation of mitogen-activated protein kinase cascade regulates pituitary tumor-transforming gene transactivation function. J Biol Chem. 2000, 275: 31191-31198.CrossRefPubMed
21.
Pei L: Identification of c-myc as a down-stream target for pituitary tumor-transforming gene. J Biol Chem. 2001, 276: 8484-8491.CrossRefPubMed
22.
Yu R, Lu W, Chen J, McCabe CJ, Medmed S: Overexpressed pituitary tumor transforming gene causes aneuploidy in live human cells. Endocrinology. 2003, 144: 4991-4998.CrossRefPubMed
23.
Bernal JA, Luna R, Espina A, Lazaro I, Ramos-Morales F, Romero F, Arias C, Silva A, Tortolero M, Pintor-Toro JA: Human securin interacts with p53 and modulates p53-mediated transcriptional activity and apoptosis. Nat Genet. 2002, 32: 306-311.CrossRefPubMed
24.
Clem AL, Hamid T, Kakar SS: Characterization of the role of Sp1 and NF-Y in differential regulation of PTTG/securin expression in tumor cells. Gene. 2003, 322: 113-121.CrossRefPubMed
25.
Zhou Y, Mehta KR, Choi AP, Scolavino S, Zhang X: DNA damage-induced inhibition of securin expression is mediated by p53. J Biol Chem. 2003, 278: 462-470.CrossRefPubMed
26.
Rokhlin OW, Bishop GA, Hostager BS, Waldschmidt TJ, Sidorenko SP, Pavloff N, Kiefer MC, Umansky SR, Glover RA, Cohen MB: Fas-mediated apoptosis in human prostatic carcinoma cell lines. Cancer Res. 1997, 57: 1758-1768.PubMed
27.
28.
Kirch HC, Flaswinkel S, Rumpf H, Brockmann D, Esche H: Expression of human p53 requires synergistic activation of transcription from the p53 promoter by AP-1, NF-kappaB and myc/max. Oncogene. 1999, 18: 2728-2738.CrossRefPubMed
29.
30.
Cole MD, McMahon SB: The Myc oncoprotein: a critical evaluation of transactivation and target gene regulation. Oncogene. 1999, 18: 2916-2924.CrossRefPubMed
31.
Amati B, Brooks MW, Levy N, Littlewood TD, Evan GI, Land H: Oncogenic activity of the c-myc protein requires dimerization with max. Cell. 1993, 72: 233-245.CrossRefPubMed
32.
33.
Nagashima M, Shiseki M, Pedeux RM, Okamura S, Kitahama-Shiseki M, Miura K, Yokota J, Harris CC: A novel PHD-finger motif protein, p47ING3, modulates p53-mediated transcription, cell cycle control, and apoptosis. Oncogene. 2003, 22: 343-350.CrossRefPubMed
34.
Lu W, Pochampally R, Chen L, Traidej M, Wang Y, Chen J: Nuclear exclusion of p53 in a subset of tumors requires MDM2 function. Oncogene. 2000, 19: 232-240.CrossRefPubMed
35.
Brooks CL, Gu W: Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr Opin Cell Biol. 2003, 15: 164-171.CrossRefPubMed
36.
Martin LJ, Price AC, McClendon KB, Al-Abdulla NA, Subramaniam JR, Wong PC, Liu Z: Early events of target deprivation/axotomy-induced neuronal apoptosis in vivo: oxidative stress, DNA damage, p53 phosphorylation and subcellular redistribution of death proteins. J Neurochem. 2003, 85: 234-247.CrossRefPubMed
37.
Buckbinder L, Talbott R, Velasco-Miguel S, Takenaka I, Faha B, Seizinger BR, Kley N: Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature. 1995, 377: 646-649.CrossRefPubMed
38.
Dominguez A, Ramos-Morales F, Romero F, Rios RM, Dreyfus F, Tortolero M, Pintor-Toro JA: hPTTG, a human homologue of rat PTTG, is overexpressed in hematopoietic neoplasms. Evidence for a transcriptional activation function of hPTTG. Oncogene. 1998, 17: 2187-2193.CrossRefPubMed
39.
40.
Juin P, Hunt A, Littlewood T, Griffiths B, Swigart LB, Korsmeyer S, Evan G: c-myc functionally cooperates with bax to induce apoptosis. Mol Cell Biol. 2002, 22: 6158-6169.PubMedCentralCrossRefPubMed
41.
Foletta VC: Transcription factor AP-1, and the role of Fra-2. Immunol Cell Biol. 1996, 74: 121-133.CrossRefPubMed
42.
Kakar SS, Chen L, Puri R, Flynn SE, Jennes L: Characterization of a polyclonal antibody to human pituitary tumor transforming gene 1 (PTTG 1) protein. J Histochem Cytochem. 2001, 49: 1537-1546.CrossRefPubMed
43.
Panek RB, Lee YJ, Itoh-Lindstrom Y, Ting JP, Benveniste EN: Characterization of astrocyte nuclear proteins involved in IFN-gamma- and TNF-alpha-mediated class II MHC gene expression. J Immunol. 1994, 153: 4555-4564.PubMed
Metadata
Title
PTTG/securin activates expression of p53 and modulates its function
Authors
Tariq Hamid
Sham S Kakar
Publication date
01-12-2004
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2004
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-3-18

Other articles of this Issue 1/2004

Molecular Cancer 1/2004 Go to the issue

Editorial

Open Access gains attention in scholar communication

Research

Mutation in mitochondrial complex I ND6 subunit is associated with defective response to hypoxia in human glioma cells

Research

Aberrant CBFA2T3B gene promoter methylation in breast tumors

Research

Can gene expression profiling predict survival for patients with squamous cell carcinoma of the lung?

Research

The proteosome inhibitor MG132 attenuates Retinoic Acid Receptor trans-activation and enhances trans-repression of Nuclear Factor κB. Potential relevance to chemo-preventive interventions with retinoids

Research

Sensitivity and reproducibility of standardized-competitive RT-PCR for transcript quantification and its comparison with real time RT-PCR
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits